A comparison of medication adherence and viral suppression in antiretroviral treatment-naïve patients with HIV/AIDS depending on the drug formulary

Kyung Sun Oh1,2, Euna Han1*

1 College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea, 2 Department of Pharmacy, Inha University Hospital, Incheon, Republic of Korea

* eunahan@yonsei.ac.kr

Abstract

Antiretroviral treatment (ART) adherence is highlighted in management of patients living with human immunodeficiency virus. In South Korea, ART medication research has rarely been conducted due to the low economic burden associated with government-funded treatment. This cross-sectional study aimed to compare the pill burden impact between ART regimen compliance and HIV-RNA viral load suppression. Data were collected from 2008 to 2016 at a general hospital in South Korea. A total of 210 HIV/AIDS treatment-naïve patients were grouped as follows: single-tablet regimen (STR, one tablet/day), mild pill burden (two-four tablets/day), and heavy pill burden (≥ five tablets/day). Patients were analyzed according to gender, age at index date, medical insurance type, comorbidities, depression, HIV/AIDS disease burden as indicated by HIV-RNA viral load and CD4, and laboratory variables. In a multivariate logistic regression model, the STR group demonstrated adherence 5.10 times more often than the heavy pill burden group. Females and patients with an initial viral load of 500,000 or more were 0.090- and 0.040-fold less adherent to the ART regimen. Among these patients, 95% or more of the MPR group were 7.38 times more likely to have a lower limit of detection (LLOD) of viral load suppression. The highest initial viral load group was 0.090-fold less likely to have an LLOD than the reference group. These results suggest that a single-tablet regimen could improve medication adherence and the clinical virologic outcome. Therefore, general population research on ART adherence and polypharmacy is needed.

Introduction

Antiretroviral therapy (ART) is the cornerstone of treatment for patients living with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) [1]. The United Kingdom Collaborative HIV Cohort Study found that HIV-positive patients who achieved viral suppression and had CD4 counts of > 350 cells/mm³ within one year of antiretroviral treatment (ART) regimen initiation had a normal life expectancy, i.e., it was estimated
that a 35-year-old patient would live past the age of 80 years [2]. It is well documented that suboptimal adherence to an ART regimen is associated with a greater risk of developing resistance to antiretroviral agents and increases in morbidity, mortality, and progression to AIDS [3]. The Joint United Nations Program on HIV/AIDS has targeted a goal of 90% medication adherence by 2020 to combat HIV infections [4].

Despite the importance of compliance with an ART regimen, adherence rates are less than optimal, ranging from 60% to 80% [5, 6]. It is recommended to maintain a high compliance rate of 90% or more in managing HIV/AIDS as a chronic disease [1, 7]. Given that all HIV/AIDS patients can be treated through government support in South Korea, they have less economic burden for antiretroviral treatment. This has led to a lack of medication research centered on investigating the relationship between medication adherence and pill burden or viral load suppression.

During the course of our study three Korean-recommended HIV/AIDS guidelines were released—in 2011, 2013, and 2015. These were developed in accordance with the European AIDS Clinical Society and IAS-USA panel strategies [8–10]. The new guidelines included offering antiretroviral treatment to all patients, regardless of their CD4+ T cell counts. Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) was introduced as a new and preferred medication in 2013. Elvitegravir/cobicistat/emtricitabine/tenofovir became available only as a single co-formulated tablet, according to the 2015 guideline.

In May 2012, TDF/FTC became available for prescription in HIV/AIDS treatment, and lamivudine (3TC)/abacavir (ABC) became available in August 2012, after its addition to the drug formulary. These simplified ART regimens have made it much easier for patients to take ART medication once a day; this is composed of two tablets of TDF/FTC in addition to efavirenz. Treatment has been further simplified with the addition to the drug formulary of single-tablet regimens such as elvitegravir/cobicistat/emtricitabine/tenofovir (originally listed in April 2014) or dolutegravir/abacavir/lamivudine (listed in March 2016). Therefore, we compared the medication possession ratio (MPR) according to sequential groupings into heavy pill burden (≥ five tablets/day), mild pill burden (two-four tablets/day), and single-tablet regimen (STR, one tablet/day) by chronological drug formulary changes.

We set out to compare ART regimen adherence with pill burden depending on the drug formulary listing of new HIV/AIDS medications. Consequently, the objective of this study was to investigate medication compliance by medication possession ratio (MPR) according to pill burden, as well as by viral load suppression by medication compliance according to MPR.

Materials and methods

Data

We extracted electronic medical record (EMR) data from a general hospital in South Korea. We selected patients who were at least 20 years of age and had been prescribed an ART regimen between January 01, 2008, and December 31, 2016. A total of 242 patients were initially identified. Of these, the ART-naïve patients were defined based on their transfer from a local public health center or a local clinic and no ART regimen prescription. So, 32 subjects were excluded because their status was not naïve in treatment for HIV/AIDS. The remaining 210 subjects were ART-naïve patients who had been referred from a local clinic to the general hospital for HIV/AIDS treatment. They would be considered for the final analysis. (Fig 1)

Variables

Patients were categorized into three groups by ART pill count. The magnitude of the pill burden group was measured with the number of tablets according to index date as follows: 1)
heavy pill burden group (≥ five tablets/day, the reference group); 2) mild pill burden group (two-four tablets/day), after TDF/FTC had been added to the drug formulary; and 3) single-tablet regimen group (STR), after the first co-formulated ART, elvitegravir/cobicistat/emtricitabine/tenofovir, had been listed in the drug formulary. The index date was defined as the first date the patient with an HIV/AIDS-related diagnosis (International Classification of Diseases-10 (ICD 10) codes B20-B24) was dispensed a highly active antiretroviral treatment (HAART) regimen. For each group, the number of pills that the patient needed to take per day was counted separately for each antiretroviral treatment. The ART regimens that had been prescribed for a minimum of 30 days after the index date and maintained during the 12–24 week period were assessed. If an ART regimen was changed during the study period, the antiretroviral pill burden was determined to be the average pill number.

We analyzed two outcomes: the degree of ART regimen adherence and viral load suppression. Adherence to the ART regimen was measured with the MPR, which is a proxy for medication compliance by pharmacy refill data. The MPR was calculated as the total number of days from the index date to the date of the viral load result and was used as the denominator. During that period, the number of days each patient had the ART available was used as a numerator [11, 12]. The MPR was calculated as follows.

\[
\frac{\sum \text{Total number of days available with antiretroviral treatment}}{\sum \text{Total number of days between the index date and the date of HIV RNA result}}
\]

Patients with an MPR of 95% or higher were considered adherent to the medication regimen [13–15]. The MPR was cut off at “1” for patients with higher than 100% adherence.
After ART medication was initiated, confirmation of the HIV-RNA viral load between week 12 and week 24 was recommended [8, 10]. The antiretroviral effect is confirmed by the lower limit of detection (LLOD) result after ART initiation. So, the viral load suppression analysis was conducted on a subset of patients who had HIV-RNA levels both on the pre-index date and during the 12–24-week period. Virologic suppression was defined as the state in which the HIV-RNA polymerase chain reaction (HIV-RNA PCR) level during the 12–24 weeks was not detected after the ART regimen was given to the patients. Virologic suppression was dichotomized with a dummy indicator representing 20 copies/ml or less defined as the lower limit of detection, to determine whether virologic suppression was achieved [16–18].

The Anderson model has been evaluated as suitable for analyzing predictive factors for the use of medical and social services. Therefore, we referenced several covariates to account for patient characteristics (predisposing factors: gender and age at index date; enabling factors: type of medical insurance; vulnerable need: depression, comorbidities) that was frequently cited in past HIV/AIDS articles [19, 20]. The HIV/AIDS disease burden was measured using the pre-index date HIV-RNA viral load and CD4 as well as laboratory variables [5, 14]. In Korea, 97% of the population must register with the mandatory National Health Insurance, and the remaining 3%, those in the lowest socioeconomic level, are covered by National Medical Aid. Given this, we used the medical insurance type to account for their financial status. As a proxy for comorbidities, we collected data on syphilis and viral hepatitis (Hepatitis B and Hepatitis C) for infectious diseases. We included all kinds of neoplasm identified at the referred outpatient visit [21]. A syphilis co-infection was confirmed by ICD-10 codes (A50–A53) and a benzathine penicillin G prescription. Viral hepatitis B or hepatitis C, chronic infectious diseases, were confirmed through ICD-10 codes (B18 or K73), and viral hepatitis medication treatment. Malignancy, including leukemia and lymphoma, was defined by diagnosis code (ICD-10 codes C00-C96; see S1 Table) and chemotherapy. The presence of depression was defined by a psychiatric consultation record and the WHO ATC code for an N06A antidepressant or N05B anxiolytics prescription [22]. As baseline characteristics, we used the HIV/AIDS disease burden and clinical laboratory data on creatinine, fasting blood glucose, lipid panel (total cholesterol, low-density lipoprotein (LDL), triglycerides (TG), and high-density lipoprotein (HDL) within the four weeks before the index date. We also created categorical variables to account for the HIV/AIDS disease burden. The CD4 count was divided into three levels: <200 (requiring prophylactic antibiotics), 200–349, and ≥350. Finally, the pre-index viral load was classified into four groups: less than 10,000, 10,000–<100,000, 100,000–<500,000, and more than 500,000.

**Statistical analysis**

This was a cross-sectional study. The patients’ demographic and clinical characteristics were compared across the three pill burden groups using the $\chi^2$ test, Fisher’s exact test, or analysis of variance, as appropriate. Logistic regression models were performed to identify the factors associated with the MPR and to evaluate the difference in viral load suppression between MPR 95% and less than according to pill burden groups and baseline covariates. All analyses were performed using STATA 15 (Stata Corp, College Station, TX, USA).

**Ethics**

This study was approved by the Institutional Review Board of Inha University Hospital (INHAUH 2018–11–011–002). All information that could identify the subject, such as name and registration number, was deleted from the electronic medical records for data confidentiality and the subject’s anonymity. The extracted data was generated and managed by
Results

A total of 242 HIV/AIDS patients were prescribed antiretroviral therapy in the years 2008–2016. Of these, 32 subjects were excluded because they were referred from other general hospitals with a non-naïve HIV/AIDS status. The remaining 210 subjects were ART-naïve patients and were included in the final analysis. The baseline characteristics of these 210 subjects are presented in Table 1.

Males predominated in all three different pill burden groups at an average of 93.2% to 96%. No statistically significant differences were found among the three groups for pre-index viral load, presence of depression, comorbidities, and all clinical laboratory data (total cholesterol, triglycerides (TG), LDL, and HDL). In the case of pre-index viral load, there was one patient without a pre-index HIV-RNA PCR, but their HIV/AIDS positive result was indicated only by the ELISA method (reference negative) [23]. In addition, there is no statistically significant difference at pre-index viral load; it showed a trend with much lower pre-index viral load over time. The average age at the beginning of the ART regimen was 43.5±13.1 for the heavy pill burden group, 43.6±12.6 for the mild pill burden group, and 37.2±11.0 for the single-tablet regimen group (p = 0.008). A posthoc test showed that the STR group was statistically different from the heavy pill burden group and the mild pill burden group. The proportion of National Medical Aid in the STR group was less than that of the heavy pill burden group because of their younger age as of the index date. (p = 0.043) These differences in the actual pill burden appeared among the three groups. The mean of the ART pill numbers per day was 7.1 ± 2.0, 2.9 ± 0.8, and one tablet for the heavy pill burden group, mild pill burden group, and the single-tablet regimen group. (p < 0.001), respectively. The ART actual pill changes over time are plotted in Fig 2. When a new blockbuster HIV/AIDS medication was added to the drug formulary, the recommended pill burden for patients gradually decreased. The number of patients that had ART regimen changes within wk12-24 was 27. Twenty-three patients had records indicating the reason for the treatment change, and four were without valid reasons for it. The rate of patients who shifted to a different formulation owing to adverse effects and lab abnormality is 11.3% for the heavy-pill group, 7.0% for the mild-pill group, and 6.0% for the single-tablet group. This is 8.6% of all 210 persons in the sample (see S2 Table).

Among the three groups, the heavy pill burden group of 47 patients (54.7%) had a CD4 count below the 200 required for prophylactic antibiotic treatment, whereas only seven (8.1%) patients had a CD4 count >350. However, in the single-tablet regimen group, the proportion of CD4 count below the 200 was 34%, and the CD4 count over the 350 was 28%, relatively (p = 0.017). These results may reflect guideline changes, including the offer of antiretroviral treatment to all patients regardless of their CD4+ T cell counts in the 2013 guidelines. Of the three groups, the total of syphilis-infected patients was 33 patients; the heavy pill group had 18 patients (20.5%), eight patients (11.1%) were in the mild pill burden group, and seven patients (14%) were in STR, respectively. The proportion of patients who were prescribed antidepressants or anti-anxiety medications for depression was similar, between 17% and 18% among the three groups, regardless of duration.

Univariate and multivariate logistic analysis indicated that gender, pre-index viral load, and antiretroviral treatment pill burden were associated with the MPR, as shown in Table 2. The univariate analysis showed that females were less likely to be adherent (unadjusted OR = 0.21,
95% CI, 0.01–0.72) than males. Patients with a higher initial viral load were less likely to be adherent (unadjusted OR = 0.08, 95% CI, 0.01–0.69). The single-tablet regimen was 6.57 times more likely to be adhered to than that of the heavy pill burden group (unadjusted OR = 6.57, 95% CI, 1.88–23.0). The multivariate logistic analysis also showed patterns similar to the findings of the univariate analyses: the single-tablet regimen was 5.10 times more likely to be

Table 1. Baseline characteristics of subjects (n = 210, n, (%) or mean ±SD).

| Variables                      | STR\(^1\) (n = 50, n (%)) | Mild pill group\(^1\) (n = 72, n (%)) | Heavy pill group\(^1\) (n = 88, n (%)) | p-value |
|-------------------------------|---------------------------|--------------------------------------|--------------------------------------|---------|
| Main independent variable     |                           |                                      |                                      |         |
| Antiretroviral treatment pill burden | 1                         | 2.9 ± 0.8                            | 7.1 ± 2.0                            | <0.001  |
| Dependent variables           |                           |                                      |                                      |         |
| Medication possession ratio   |                           |                                      |                                      |         |
| ≥ 95%                         | 47 (94.0)                 | 55 (76.4)                            | 62 (70.4)                            | 0.002   |
| < 95%                         | 3 (6.0)                   | 17 (23.6)                            | 26 (29.6)                            |         |
| Viral load suppression (LLOD, lower limit of detection) |                           |                                      |                                      |         |
| Yes                           | 39 (78.0)                 | 47 (65.3)                            | 45 (37.5)                            | 0.011   |
| No                            | 8 (16.0)                  | 20 (27.8)                            | 33 (42.3)                            |         |
| Covariates                    |                           |                                      |                                      |         |
| Pre-index viral load          |                           |                                      |                                      |         |
| <10,000                       | 8(16.0)                   | 7 (9.7)                              | 7 (8.1)                              | 0.200   |
| 10,000 - <100,000             | 29 (58.0)                 | 29 (40.3)                            | 40 (45.9)                            |         |
| 100,000 - <500,000            | 10 (20.0)                 | 28 (38.9)                            | 30 (34.5)                            |         |
| ≥500,000                      | 3 (6.0)                   | 8 (11.1)                             | 10 (11.5)                            |         |
| Pre-index CD4 count           |                           |                                      |                                      |         |
| <200                          | 17 (34.0)                 | 32 (44.4)                            | 47 (54.7)                            | 0.017   |
| 200–349                       | 19 (38.0)                 | 24 (33.3)                            | 32 (37.2)                            |         |
| ≥350                          | 14 (28.0)                 | 16 (22.3)                            | 7 (8.1)                              |         |
| Gender                        |                           |                                      |                                      |         |
| Male                          | 48 (96.0)                 | 69 (95.8)                            | 82 (93.2)                            | 0.729   |
| Female                        | 2 (4.0)                   | 3 (4.2)                              | 6 (6.8)                              |         |
| Age at index date             | 37.2 ± 11.0               | 43.6 ± 12.6                          | 43.5 ± 13.1                          | 0.008   |
| Medical insurance type        |                           |                                      |                                      |         |
| National Health Insurance     | 48 (96.0)                 | 59 (81.9)                            | 73 (82.9)                            | 0.043   |
| National Medical Aid          | 2 (4.0)                   | 13 (18.1)                            | 15 (17.1)                            |         |
| Depression                    | 9 (18.0)                  | 13 (18.1)                            | 15 (17.1)                            | 0.983   |
| Comorbidity                   |                           |                                      |                                      |         |
| Syphilis                      | 7 (14.0)                  | 8 (11.1)                             | 18 (20.5)                            | 0.252   |
| Viral hepatitis               | 1 (2.0)                   | 2 (2.8)                              | 3 (3.4)                              | 0.891   |
| Malignancy                    | 0 (0.0)                   | 3 (4.2)                              | 3 (3.4)                              | 0.400   |
| Clinical Laboratory           |                           |                                      |                                      |         |
| Creatinine                    | 0.93 ± 0.15               | 1.01 ± 0.34                          | 0.98 ± 0.17                          | 0.171   |
| Fasting Blood Glucose         | 105.9 ± 52.2              | 107.2 ± 32.8                         | 106.9 ± 31.3                         | 0.982   |
| Total Cholesterol             | 147.7 ± 32.8              | 148.7 ± 35.4                         | 156.6 ± 32.4                         | 0.212   |
| Triglycerides                 | 136.9 ± 98.9              | 165.4 ± 95.5                         | 174.1 ± 106.6                        | 0.129   |
| Low-density lipoprotein       | 92.0 ± 27.8               | 89.6 ± 27.2                          | 94.1 ± 25.7                          | 0.633   |
| High-density lipoprotein      | 39.6 ± 14.1               | 36.2 ± 10.8                          | 40.1 ± 12.6                          | 0.159   |

1) STR: Single tablet regimen group, Mild pill group: two-four tablets/day, Heavy pill group: ≥ five tablets/day. 
P-value estimated using \(\chi^2\) test, Fisher’s exact test in categorical variables and analysis of variance in continuous variables.

https://doi.org/10.1371/journal.pone.0245185.t001
adhered to than that of the heavy pill burden group (adjusted OR = 5.10, 95% CI, 1.32–19.7). Female patients were 0.09-fold less likely to adhere to the ART regimen (95% CI, 0.02–0.44) as compared with male patients. Those with an initial viral load of 500,000 or more also were 0.040-fold less likely to adhere to (95% CI, 0.01–0.56) than the reference group with an initial viral load of less than 10,000 (Table 2).

A binary logistic regression analysis on viral load suppression revealed that the pre-index viral load and medication compliance of 95% or higher were important factors, as shown in Table 3. We obtained HIV-RNA PCR results for 192 patients at both the pre-index date and during 12–24 weeks. In the 12–24-week test, 118 patients with a 95% or higher MPR had an LLOD, and 33 patients failed, whereas in the less than the 95% MPR group, only 13 patients achieved LLOD; 28 patients did not.

In the unadjusted analysis, a group with 95% or higher MPR was 7.74 times more likely to have viral load suppression (95% CI, 3.59–16.5). In contrast, a high pre-index viral load (≥500,000) was 0.060-fold less likely to have virologic suppression (95% CI, 0.01–0.36). Such results were parallel with the multivariate logistic analysis. Patients with a 95% or higher MPR were 7.38 times more likely to have viral load suppression than those with an MPR of lower than 95% (95% CI, 2.84–19.2). The group with a pre-index viral load of 500,000 or more was 0.09-fold less likely to have viral load suppression (95% CI, 0.01–0.59) than that with a pre-index viral load of less than 10,000. In contrast, unlike the results of the univariate logistic regression analysis, the antiretroviral treatment pill burden group did not show a statistically significant association with the viral load suppression in multivariate logistic regression analysis (Table 3).

Discussion

We investigated the relation between pill burden and medication adherence and viral load suppression. In particular, we assessed whether a gradual change in pill burden, based on drug
formulary changes from more than five tablets a day (heavy pill burden) to two-four tablets (mild pill burden) or a single-tablet level, was associated with a higher rate of medication adherence and virologic suppression.

Our findings showed that a lower pill burden, a lower HIV-RNA level, and male patients were associated with higher medication adherence. Patients who had a higher initial viral level had a lower MPR. In addition, the MPR of the lower pill burden group as STR was higher than that of the heavy pill burden group. These are parallel with the results of other global studies comparing the MPR of STR and MTR for drug compliance [7, 24, 25]. In this study, female patients were associated with lower medication adherence. This also coincides with the results of previous studies on the Korean population in which the female group characterized by lower medication adherence [5, 26]. In addition, this study found that good medication

Table 2. Factors associated with MPR (medication possession ratio) (n = 210).

| Variables                      | Univariate logistic analysis OR (95% CI) MPR ≥ 95% (n = 164) | Multivariate logistic analysis OR (95% CI) MPR ≥ 95% (n = 164) |
|--------------------------------|-------------------------------------------------------------|---------------------------------------------------------------|
| Antiretroviral treatment       |                                                             |                                                               |
| Pill burden                    |                                                             |                                                               |
| Heavy pill burden group \(^1\) | Reference                                                   | Reference                                                     |
| Mild pill burden group \(^1\)  | 1.36 (0.67–2.76)                                            | 1.24 (0.56–2.75)                                             |
| Single tablet regimen \(^1\)   | 6.57 (1.88–23.0)                                            | 5.10 (1.32–19.7)                                             |
| Gender                         |                                                             |                                                               |
| Male                           | Reference                                                   | Reference                                                     |
| Female                         | 0.21 (0.01–0.72)                                            | 0.09 (0.02–0.44)                                             |
| Age at index date              | 0.99 (0.97–1.02)                                            | 0.99 (0.96–1.02)                                             |
| Medical insurance type         |                                                             |                                                               |
| National Health Insurance      | Reference                                                   | Reference                                                     |
| National Medical Aid           | 0.50 (0.21–1.16)                                            | 0.81 (0.29–2.26)                                             |
| Pre-index viral load           |                                                             |                                                               |
| <10,000                        | Reference                                                   | Reference                                                     |
| 10,000 - <100,000              | 0.18 (0.02–1.46)                                            | 0.10 (0.01–1.17)                                             |
| 100,000 - <500,000             | 0.15 (0.01–1.24)                                            | 0.09 (0.01–1.11)                                             |
| ≥500,000                       | 0.08 (0.01–0.69)                                            | 0.04 (0.01–0.56)                                             |
| Pre-index CD4 count            |                                                             |                                                               |
| <200                           | Reference                                                   | Reference                                                     |
| 200–349                        | 1.59 (0.75–3.38)                                            | 0.91 (0.39–2.14)                                             |
| ≥350                           | 1.21 (0.49–2.99)                                            | 0.89 (0.26–2.81)                                             |
| Depression                     | 0.71 (0.31–1.60)                                            | 0.59 (0.24–1.48)                                             |
| Comorbidity                    |                                                             |                                                               |
| Syphilis                       | 0.85 (0.34–2.05)                                            | 0.83 (0.29–2.33)                                             |
| Viral hepatitis                 | 0.27 (0.05–1.37)                                            | 0.12 (0.01–0.89)                                             |
| Malignancy                     | 0.27 (0.05–1.37)                                            | 0.49 (0.07–3.62)                                             |

1) STR: Single tablet regimen group, Mild pill group: two-four tablets/day, Heavy pill group: ≥ five tablets/day.

https://doi.org/10.1371/journal.pone.0245185.t002
adherence (95% or higher MPR) and lower initial viral load indicated a higher rate of viral load suppression. Of the total 210 patients, the 118 patients in the 95% or higher MPR group achieved viral load suppression. In the lower than 95% MPR group, only 13 patients reached an LLOD. According to previous studies, the MPR is closely associated with the virologic failure rate [27–30]. During the study period from 2008 to 2016, the rate of HIV/AIDS patients with depression did not change significantly, remaining between 17% to 18%. According to previous studies about depression and AIDS, social stigma related to HIV/AIDS causes depression and anxiety, which may not only provoke suicidal ideation but reduce medication adherence.

Table 3. Factors associated with viral load suppression (Lower Limit of Detection (LLOD)) (n = 192).

| Variables                           | Univariate logistic analysis viral load suppression (LLOD), (95% CI) | Multivariate logistic analysis viral load suppression (LLOD), OR (95% CI) |
|-------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------|
| Medication possession ratio         |                                                                    |                                                                       |
| <95%                                | Reference                                                          | Reference                                                             |
| ≥95%                                | 7.74 (3.59–16.5)                                                   | 7.38 (2.84–19.2)                                                     |
| Antiretroviral treatment            |                                                                    |                                                                       |
| Pill burden                         |                                                                    |                                                                       |
| Heavy pill burden group1)           | Reference                                                          | Reference                                                             |
| Mild pill burden group1)            | 1.72 (0.86–3.43)                                                   | 1.80 (0.75–4.28)                                                     |
| STR1)                              | 3.56 (1.48–8.65)                                                   | 1.78 (0.60–5.27)                                                     |
| Gender                              |                                                                    |                                                                       |
| Male                                | Reference                                                          | Reference                                                             |
| Female                              | 0.36 (0.11–1.24)                                                   | 0.34 (0.07–1.59)                                                     |
| Age at index date                   | 0.99 (0.97–1.01)                                                   | 0.99 (0.96–1.02)                                                     |
| Medical insurance type              |                                                                    |                                                                       |
| National Health Insurance           | Reference                                                          | Reference                                                             |
| National Medical Aid                | 0.92 (0.40–2.10)                                                   | 0.99 (0.32–3.09)                                                     |
| Pre-index viral load                |                                                                    |                                                                       |
| <10,000                             | Reference                                                          | Reference                                                             |
| 10,000 - <100,000                   | 0.40 (0.09–1.90)                                                   | 0.86 (0.18–4.16)                                                     |
| 100,000 - <500,000                  | 0.11 (0.02–0.49)                                                   | 0.22 (0.04–1.09)                                                     |
| ≥500,000                            | 0.06 (0.01–0.36)                                                   | 0.09 (0.01–0.59)                                                     |
| Initial CD4 count                   |                                                                    |                                                                       |
| <200                                | Reference                                                          | Reference                                                             |
| 200–349                             | 1.32 (0.68–2.61)                                                   | 0.76 (0.32–1.82)                                                     |
| >350                                | 2.54 (1.00–6.45)                                                   | 1.66 (0.47–5.87)                                                     |
| Depression                          | 0.92 (0.41–2.03)                                                   | 1.07 (0.37–3.04)                                                     |
| Comorbidity                         |                                                                    |                                                                       |
| Syphilis                            | 1.82 (0.74–4.47)                                                   | 2.18 (0.64–7.44)                                                     |
| Viral hepatitis                     | 0.46 (0.06–3.33)                                                   | 0.96 (0.10–9.67)                                                     |
| Malignancy                          | 0.93 (0.17–5.21)                                                   | 4.05 (0.25–65.1)                                                     |

1) STR: Single tablet regimen group, Mild pill group: two-four tablets/day, Heavy pill group: ≥ five tablets/day.

https://doi.org/10.1371/journal.pone.0245185.t003
To reduce the number of HIV/AIDS patients with depression and improve ART compliance, HIV/AIDS-related knowledge should be increased, and HIV/AIDS-related stigma must be reduced.

This study has several limitations. First, we analyzed a small sample of 210 individuals, which is too small to represent the general Korean population. From 2008 to 2016, an average number of 20–30 HIV/AIDS-naive patients were enrolled in the institution from which our data were extracted, excluding patients who had transferred while already in HIV/AIDS treatment. Considering that 1,191 new HIV/AIDS subjects were registered in 2017 across Korea, this means that our study sample accounted for only approximately 2.5% of all newly-enrolled HIV/AIDS patients nationwide [33]. Furthermore, 18 patients or approximately 8.5% of the 210 subjects who were initially included in our study did not have outpatient visits during weeks 12–24; therefore, they were excluded from the final virologic suppression analysis owing to a lack of HIV-RNA PCR data during that period. However, as the majority of the 18 patients were successfully treated, showing a lower viral load of fewer than 100 copies/ml before week 12 (two patients obtained LLOD earlier within wk4 and five patients' HIV-RNA level was 20–99 copies/ml), so their outpatient follow-up visit interval was extended to more than three months. As for the 18 patients, there were 13 patients with a HIV-RNA PCR before wk12, four patients with LLOD results after wk24, and only one patient without a pre-index HIV-RNA viral load. Additionally, five of the total 18 patients obtained LLOD at the first HIV-RNA PCR after taking ART, with two obtaining LLOD earlier within wk4. However, this does not make any significant statistical difference in MPR and viral load suppression if we conduct additional analysis of the total of 210 subjects. This study used the MPR as the indicator of medication adherence because it is appropriate for HIV/AIDS patients who generally receive multiple ART medications in the same outpatient visit. However, the MPR has its own limitation in that it can be measured only based on the ART dispensing record. Thus, it is not possible to ascertain whether patients actually take their ART medication [29, 34]. Finally, second-generation antiretroviral medications or single-tablet regimens have lower toxicities and lower viral resistance rates, which contribute to better medication adherence and the viral suppression effect. The improved effectiveness of newer ART medication is consistent with our research finding that compared to the heavy pill burden group, the single-tablet group sustained a higher level of medication adherence and viral load suppression.

Despite these limitations, our study provides a significant finding regarding the relationship between pill burden and ART adherence. According to the results, the lower pill burden represented by taking STR and the lower HIV/AIDS disease burden represented by the lower initial viral load were associated with better medication adherence and virologic suppression. These results suggest that the STR could improve medication adherence and clinical virologic outcomes, as we expected. As HIV/AIDS patients continue to live longer, it is becoming increasingly important to manage medication adherence and concomitant medications effectively; therefore, further research on ART adherence and polypharmacy is needed for the general population.

**Supporting information**

S1 Table. ICD-10 codes associated with covariates.

S2 Table. The number of patients who had an antiretroviral treatment change within wk12–24.

(DOCX)
Author Contributions

Conceptualization: Kyung Sun Oh, Euna Han.
Data curation: Kyung Sun Oh.
Formal analysis: Kyung Sun Oh.
Funding acquisition: Euna Han.
Investigation: Euna Han.
Methodology: Euna Han.
Supervision: Euna Han.
Validation: Euna Han.
Writing – original draft: Kyung Sun Oh.
Writing – review & editing: Euna Han.

References

1. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2016 recommendations of the international antiviral society–usa panel. JAMA. 2016; 316 (2):191–210. https://doi.org/10.1001/jama.2016.8900 PMID: 27404187
2. May M, Gompels M, Sabin C. Life expectancy of HIV-1-positive individuals approaches normal condition on response to antiretroviral therapy: UK Collaborative HIV Cohort Study. Journal of the International AIDS Society. 2012; 15(Suppl 4):18078.
3. Cheng Y, Sauer B, Zhang Y, Nickman NA, Jamjian C, Stevens V, et al. Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection. Medicine (Baltimore). 2018; 97(2):e9430. https://doi.org/10.1097/MD.0000000000009430 PMID: 29480831
4. HIV/AIDS JUNPo, HIV/Aids JUNPo. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: UnAids. 2014.
5. Kim J, Lee E, Park BJ, Bang JH, Lee JY. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009–2016: A nationwide study. Scientific Reports. 2018; 8(1):3133. https://doi.org/10.1038/s41598-018-21081-x PMID: 29453993
6. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013; 3(8).
7. Cheng Y, Nickman NA, Jamjian C, Stevens V, Zhang Y, Sauer B, et al. Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus. Medicine (Baltimore). 2018; 97(2):e9495. https://doi.org/10.1097/MD.0000000000009495 PMID: 29480838
8. Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-infected Koreans. Infection and Chemotherapy. 2011; 43(2).
9. Korean Society for A. The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother. 2013; 45(4):455–61. https://doi.org/10.3947/ic.2013.45.4.455 PMID: 24475362
10. Korean Society for A. The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother. 2015; 47(3):205–11. https://doi.org/10.3947/ic.2015.47.3.205 PMID: 26483998
11. Fairman KA, Matheral BJJomcp. Evaluating medication adherence: which measure is right for your program? 2000; 6(6):499–506.
12. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. Journal of Clinical Epidemiology. 1997; 50(1):105–16. https://doi.org/10.1016/s0895-4356(96)00268-5 PMID: 9048695
13. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine. 2000; 133(1):21–30. https://doi.org/10.7326/0003-4819-133-1-200007040-00004 PMID: 10877736
14. Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017; 37(2):204–13.

15. Tandon N, Mao J, Shprecher A, Anderson AJ, Cao F, Jiao X, et al. Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV. Curr Med Res Opin. 2019; 35(1):63–71. https://doi.org/10.1080/03007995.2018.1519499 PMID: 30173561

16. DHHS guideline_Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.pdf

17. Gunthard HF, Saag MS, Benson CA, del Rio C, Cahn P, Eron JJ, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016; 316(2):191–210. https://doi.org/10.1001/jama.2016.8900 PMID: 27404187

18. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection; 2012 recommendations of the International Antiviral Society–USA panel. JAMA. 2012; 308(4):387–402. https://doi.org/10.1001/jama.2012.7961 PMID: 22820792

19. Anderson JG. Health services utilization: framework and review. Health Serv Res. 1973; 8(3):184–99. PMID: 493850

20. Anthony MN, Gardner L, Marks G, Anderson-Mahoney P, Metsch LR, Valverde EE, et al. Factors associated with use of HIV primary care among persons recently diagnosed with HIV: examination of variables from the behavioural model of health-care utilization. AIDS Care. 2007; 19(2):195–202. https://doi.org/10.1080/09540120600966182 PMID: 17364398

21. Lee E, Kim J, Bang JH, Lee JY, Cho S-i. Association of HIV-syphilis coinfection with optimal antiretroviral adherence: a nation-wide claims study. AIDS Care. 2020; 32(5):651–5. https://doi.org/10.1080/0954012019.1686602 PMID: 31690082

22. Yun LWH, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2005; 38(4):432–8. https://doi.org/10.1093/01/47524.1912. PMID: 15764960

23. Kee M-K, Lee J-H, Whang J, Kim SS. Ten-year trends in HIV prevalence among visitors to public health centers under the National HIV Surveillance System in Korea, 2000 to 2009. BMC Public Health. 2012; 12(1):831. https://doi.org/10.1186/1471-2458-12-831 PMID: 23020818

24. Zhou S, Martin K, Napravnik S, Eron J, Zhu Y, et al. Total daily pill burden in HIV-infected patients in the southern United States. AIDS Patient Care STDs. 2014; 28(6):311–7. https://doi.org/10.1089/apc.2014.0165 PMID: 26923931

25. Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AF, Santoro A, et al. Impact of polypharmacy on antiretroviral prescription in people living with HIV. J Antimicrob Chemother. 2017; 72(2):511–4. https://doi.org/10.1093/jac/dkw437 PMID: 27834193

26. Yang HJ, Bang JH. Factors associated with medication adherence in patients with human immunodeficiency virus in South Korea. AIDS Care. 2017; 29(10):1315–9. https://doi.org/10.1080/09540121.2017.1282104 PMID: 28127987

27. Scott Sutton S, Magagnoli J, Hardin JW. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy. Pharmacotherapy. 2016; 36(4):385–401. https://doi.org/10.1002/phar.1725 PMID: 26923931

28. Gordon LL, Ghanibian D, Chong K, Chun H. Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types. AIDS Patient Care STDs. 2015; 29(7):384–8. https://doi.org/10.1089/apc.2014.0165 PMID: 26146665

29. Cooke CE, Lee HY, Xing S. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. J Manag Care Pharm. 2014; 20(1):86–92. https://doi.org/10.18553/jmcp.2014.20.1.86 PMID: 24372462

30. Yager J, Faragon J, McGuey L, Hoye-Simek A, Hecox Z, Sullivan S, et al. Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus. AIDS Patient Care STDs. 2017; 31(9):370–6. https://doi.org/10.1089/apc.2017.0081 PMID: 28771025

31. Kang CR, Bang JH, Cho S-I, Kim KN, Lee H-j, Ryu BY, et al. Suicidal ideation and suicide attempts among human immunodeficiency virus-infected adults: differences in risk factors and their implications. AIDS Care. 2016; 28(3):306–13. https://doi.org/10.1080/09540121.2015.1039393 PMID: 26444525

32. Akincigil A, Wilson IB, Walkup JT, Siegel MJ, Huang C, Crystal S. Antidepressant treatment and adherence to antiretroviral medications among privately insured persons with HIV/AIDS. AIDS and Behavior. 2011; 15(8):1819–28. https://doi.org/10.1007/s10461-011-9938-6 PMID: 21494284
33. Choi BY, Choi JY, Han SH, Kim SI, Kee M-K, Kim MJ, et al. Korea HIV/AIDS Cohort Study: study design and baseline characteristics. Epidemiology and Health. 2018; 40:e2018023-e. https://doi.org/10.4178/epih.e2018023 PMID: 30134649

34. Osterberg L, Blaschke T. Adherence to Medication. New England Journal of Medicine. 2005; 353 (5):487–97. https://doi.org/10.1056/NEJMra050100 PMID: 16079372